[Effects by androgen suppression with luteinizing hormone on cognitive functions in men treated for cancer of prostate].

Abstract

OBJECTIVE:

To evaluate secondary effects on cognitive functions as memory and attention impairments in men treated by androgen suppression for cancer of prostate.

MATERIAL AND METHODS:

A prospective study on men treated with luteinizing hormone-realising hormone analogues (LH-RH analogues) for cancer of prostate was designed. Eighteen men were evaluated with cognitive tests as Mini Mental State (MMS), memory evaluation (Grober-Buschke, Rey Test), attention and executive test (Trail Making Test and Montgomery Asberg Depression Rating Scale [MADRS]) before beginning androgen suppression. Base line pretreatment assessments of every patient were compared with similar tests after six and 12 months of hormone therapy.

RESULTS:

On 18 patients, 14 were eligible with pretreatment-median PSA of 22ng/ml (13-659), testosterone of 477ng/dl (398-583), which decreased to 1 and 37ng/dl, respectively. Visual-memory test (Rey test) was significantly improved at M6 (p: 0,001) and M12 (p: 0,02) as was the inversed number-memory test (WAIS) after M6 of androgen suppression and (p: 0,03).

CONCLUSION:

After 12 months of androgen suppression, global cognitive performances were preserved. Our results failed to observe impairment of cognitive function. This deserves more important prospective study.

• Authors: C Nedelec, S Ragot, J Irani, C Pires, R Gil, B Doré
• Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie (Prog Urol) Vol. 19 Issue 1 Pg. 47-53 (Jan 2009) ISSN: 1166-7087 [Print] France
• Vernacular Title: Effet de la suppression androgénique par agonistes de la LH-RH sur les fonctions cognitives de patients atteints de cancer de prostate.
• PMID: 19135642 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Androgen Antagonists
• Gonadotropin-Releasing Hormone

Topics

• Adenocarcinoma (drug therapy)
• Aged
• Aged, 80 and over
• Androgen Antagonists (pharmacology, therapeutic use)
• Cognition (drug effects)
• Gonadotropin-Releasing Hormone (analogs & derivatives)
• Humans
• Male
• Memory (drug effects)
• Prospective Studies
• Prostatic Neoplasms (drug therapy)